Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HMT002
MIFTS: 64

Hematologic Cancer

Categories: Blood diseases, Cancer diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hematologic Cancer

About this section

MalaCards integrated aliases for Hematologic Cancer:

Name: Hematologic Cancer 12 55 15 38
Hematologic Neoplasm 12 29 6
Hematologic Malignancies 55 15
Hematologic Neoplasms 44 72
Hematopoietic and Lymphoid System Tumor 12
Malignant Hematopoietic Neoplasm 12
Hematopoietic Neoplasms 72
Hematologic Malignancy 12
Hematopoietic Neoplasm 12
Hematological Tumors 12
Hematopoietic Cancer 12
Hematopoietic Tumors 12
Blood Cancer 12
Liquid Tumor 72

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2531
MeSH 44 D019337
NCIt 50 C27134
UMLS 72 C0376544 C0376545 C3890429
Sources

Summaries for Hematologic Cancer

About this section
Disease Ontology : 12 An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.

MalaCards based summary : Hematologic Cancer, also known as hematologic neoplasm, is related to bone marrow cancer and 8p11 myeloproliferative syndrome. An important gene associated with Hematologic Cancer is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Endometrial cancer. The drugs Basiliximab and Meropenem have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Sources

Related Diseases for Hematologic Cancer

About this section

Diseases related to Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 846, show less)
# Related Disease Score Top Affiliating Genes
1 bone marrow cancer 33.7 RUNX1 MPL KMT2A KIT JAK2 IL3
2 8p11 myeloproliferative syndrome 33.4 RUNX1 KIT FLT3
3 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 33.2 RUNX1 KMT2A KIT FLT3 ETV6
4 leukemia, acute myeloid 32.5 WT1 RUNX1 NUP98 MPL MLLT10 KMT2A
5 lymphocytic leukemia 32.3 RUNX1 KMT2A IL2 ETV6
6 aplastic anemia 32.3 MPL IL3 IL2 FLT3 CSF2
7 myeloma, multiple 32.2 PVT1 KIT JAK2 IL2 CSF2
8 refractory anemia 32.2 RUNX1 MPL JAK2 IL3
9 leukemia 32.2 WT1 RUNX1 MPL KIT JAK2 FLT3
10 acute leukemia 32.2 WT1 RUNX1 MLLT10 KMT2A KIT JAK2
11 myelodysplastic syndrome 32.1 WT1 RUNX1 NUP98 MPL KMT2A KIT
12 myeloid leukemia 32.1 WT1 RUNX1 NUP98 KIT JAK2 IL3
13 leukemia, acute lymphoblastic 32.0 RUNX1 KMT2A FLT3 ETV6 ABL1
14 myeloid sarcoma 32.0 KMT2A KIT FLT3
15 leukemia, acute monocytic 31.9 NUP98 MLLT10 KMT2A
16 juvenile myelomonocytic leukemia 31.8 RUNX1 JAK2 FLT3 CSF2 CBL
17 leukemia, chronic myeloid 31.8 WT1 RUNX1 NUP98 MPL KMT2A KIT
18 lymphoma, non-hodgkin, familial 31.7 JAK2 IL3 IL2 CSF2
19 blood platelet disease 31.7 RUNX1 MPL JAK2
20 thrombocytosis 31.6 MPL JAK2 IL3 CSF2
21 precursor t-cell acute lymphoblastic leukemia 31.6 NUP98 MLLT10 KMT2A FLT3 ETV6 ABL1
22 myelofibrosis 31.5 MPL KIT JAK2 IL3 FLT3
23 megakaryocytic leukemia 31.5 RUNX1 JAK2 IL3 CSF2
24 chronic myelomonocytic leukemia 31.4 RUNX1 KIT JAK2 FLT3 ETV6 CSF2
25 renal cell carcinoma, nonpapillary 31.4 WT1 PVT1 PTHLH KIT IL2 FLT3
26 leukemia, acute lymphoblastic 3 31.3 RUNX1 KMT2A FLT3 ETV6 ABL1
27 polycythemia vera 31.3 MPL KIT JAK2 IL3 ABL1
28 chronic eosinophilic leukemia 31.3 WT1 KIT FLT3 ABL1
29 neutrophilia, hereditary 31.3 PTHLH JAK2 FLT3 CSF2
30 myeloproliferative neoplasm 31.3 MPL KIT JAK2 ABL1
31 polycythemia 31.3 MPL JAK2 IL3
32 childhood leukemia 31.3 RUNX1 KMT2A ETV6 ABL1
33 acute promyelocytic leukemia 31.2 WT1 RUNX1 PVT1 IL3 FLT3
34 essential thrombocythemia 31.2 MPL JAK2 IL3 ABL1
35 acute myeloblastic leukemia with maturation 31.2 KIT FLT3
36 gastrointestinal stromal tumor 31.2 KIT FLT3 CCDC26 ABL1
37 severe congenital neutropenia 31.2 JAK2 IL3 CSF2
38 malignant glioma 31.1 XIST PVT1 CCDC26
39 pancytopenia 31.1 MPL IL3 CSF2
40 hypereosinophilic syndrome 31.1 KIT IL3 CSF2 ABL1
41 diphtheria 30.9 IL3 IL2 CSF2
42 retinitis pigmentosa and erythrocytic microcytosis 30.8 JAK2 IL3
43 sarcoidosis 1 30.7 IL3 IL2 CSF2
44 central nervous system hematologic cancer 12.5
45 refractory hematologic cancer 12.5
46 obsolete: hereditary thrombocytopenia-hematological cancer predisposition syndrome 12.3
47 myeloproliferative/lymphoproliferative neoplasms, familial 11.9
48 mismatch repair cancer syndrome 11.7
49 adult t-cell leukemia 11.5
50 fusariosis 11.5
51 peripheral t-cell lymphoma 11.5
52 thrombocytopenia 5 11.5
53 lymphoma 11.4
54 platelet disorder, familial, with associated myeloid malignancy 11.3
55 ras-associated autoimmune leukoproliferative disorder 11.3
56 systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease 11.3
57 core binding factor acute myeloid leukemia 11.3 WT1 RUNX1 KIT JAK2 FLT3 CBL
58 primary polycythemia 11.2 MPL JAK2 IL3 ABL1
59 acute myeloid leukemia with t(8;21)(q22;q22) translocation 11.2 RUNX1 KIT FLT3
60 leukocyte disease 11.2 KIT IL3 IL2 CSF2
61 cytogenetically normal acute myeloid leukemia 11.2 WT1 KMT2A FLT3
62 hypereosinophilic syndrome, idiopathic 11.2 WT1 KIT IL3
63 congenital mesoblastic nephroma 11.2 WT1 KIT ETV6
64 rothmund-thomson syndrome 11.2
65 anemia, sideroblastic, 1 11.2
66 surfactant metabolism dysfunction, pulmonary, 4 11.2
67 mikulicz disease 11.2
68 scleredema adultorum 11.2
69 sideroblastic anemia 11.2
70 paroxysmal cold hemoglobinuria 11.2
71 atypical chronic myeloid leukemia 11.1 RUNX1 JAK2 ABL1
72 dysgerminoma 11.1 WT1 PTHLH KIT
73 dysgerminoma of ovary 11.1 WT1 PTHLH KIT
74 malignant mesenchymoma 11.1 WT1 KIT ETV6
75 pulmonary alveolar proteinosis, acquired 11.1
76 central nervous system leukemia 11.1
77 central nervous system lymphoma 11.1
78 mast cell neoplasm 11.1
79 histiocytic and dendritic cell cancer 11.1
80 refractory hairy cell leukemia 11.1
81 acquired pure red cell aplasia 11.1
82 ring chromosome 21 11.1 KMT2A ETV6
83 subacute myeloid leukemia 11.1 JAK2 FLT3
84 testicular gonadoblastoma 11.1 WT1 KIT
85 seborrheic infantile dermatitis 11.0 IL3 CSF2
86 maxillary sinus adenoid cystic carcinoma 11.0 KIT IL2
87 chromosome 5q deletion syndrome 11.0
88 necrobiotic xanthogranuloma 11.0
89 b-cell childhood acute lymphoblastic leukemia 11.0 RUNX1 ETV6
90 ocular melanoma 10.9 KIT IL2
91 erythrocytosis, familial, 1 10.9
92 temporal arteritis 10.9
93 fanconi anemia, complementation group a 10.9
94 mycosis fungoides 10.9
95 poikiloderma with neutropenia 10.9
96 lymph node cancer 10.9
97 dyskeratosis congenita 10.9
98 erdheim-chester disease 10.9
99 monoclonal gammopathy of uncertain significance 10.9
100 sezary's disease 10.9
101 clpb deficiency 10.9
102 bone marrow necrosis 10.9
103 primary agammaglobulinemia 10.9
104 vasculitis syndromes of the central and peripheral nervous systems 10.9
105 lymphomatous meningitis 10.9
106 ovarian small cell carcinoma 10.8 WT1 PTHLH
107 diffuse peritoneal leiomyomatosis 10.8 WT1 KIT
108 capillary disease 10.7 IL2 CSF2
109 t-cell leukemia 10.5
110 peritoneal benign neoplasm 10.5 WT1 KIT
111 leukemia, t-cell, chronic 10.5
112 burkitt lymphoma 10.4
113 mucormycosis 10.4
114 toxic shock syndrome 10.4
115 hepatic veno-occlusive disease 10.4
116 candidiasis 10.4
117 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.4
118 cutaneous t cell lymphoma 10.3
119 granulocytopenia 10.3
120 autoimmune disease 10.3
121 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.3
122 pneumonia 10.3
123 lymphopenia 10.3
124 lymphoblastic lymphoma 10.3
125 leukemia, chronic lymphocytic 10.3
126 deficiency anemia 10.3
127 neuropathy 10.3
128 splenomegaly 10.3
129 cytomegalovirus infection 10.3
130 leukemia, b-cell, chronic 10.3
131 acute t cell leukemia 10.3
132 hyperuricemia 10.2
133 acute kidney failure 10.2
134 lymphoma, hodgkin, classic 10.2
135 peripheral nervous system disease 10.2
136 monocytic leukemia 10.2
137 cytokine deficiency 10.2
138 marginal zone b-cell lymphoma 10.2
139 lymphoproliferative syndrome 10.2
140 constipation 10.2
141 stomatitis 10.2
142 retinoblastoma 10.2
143 familial retinoblastoma 10.2
144 cll/sll 10.2
145 chickenpox 10.2
146 acute monoblastic leukemia 10.2
147 herpes simplex 10.2
148 hemosiderosis 10.1
149 47,xyy 10.1
150 acute respiratory distress syndrome 10.1
151 encephalopathy 10.1
152 b-cell lymphoma 10.1
153 hemophagocytic lymphohistiocytosis 10.1
154 hepatitis c 10.1
155 hemolytic anemia 10.1
156 amyloidosis 10.1
157 alopecia 10.1
158 germ cells tumors 10.1
159 stenotrophomonas maltophilia infection 10.1
160 rare hereditary hemochromatosis 10.1
161 breast cancer 10.1
162 hypothyroidism 10.1
163 pneumothorax 10.1
164 bilirubin metabolic disorder 10.1
165 hyperglycemia 10.1
166 t-cell adult acute lymphocytic leukemia 10.1
167 48,xyyy 10.1
168 engraftment syndrome 10.1
169 b-cell non-hodgkin lymphoma 10.1
170 systemic lupus erythematosus 10.0
171 neurofibromatosis, type iv, of riccardi 10.0
172 down syndrome 10.0
173 wilms tumor 5 10.0
174 hepatitis c virus 10.0
175 castleman disease 10.0
176 thalassemia 10.0
177 sarcoma 10.0
178 lactic acidosis 10.0
179 hypokalemia 10.0
180 kidney disease 10.0
181 lung disease 10.0
182 pemphigus 10.0
183 toxoplasmosis 10.0
184 refractory anemia with excess blasts in transformation 10.0
185 aspergillosis 10.0
186 kaposi sarcoma 10.0
187 thrombophilia due to thrombin defect 10.0
188 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
189 immune deficiency disease 10.0
190 neuroblastoma 1 10.0
191 helix syndrome 10.0
192 trichosporonosis 10.0
193 inflammatory bowel disease 10.0
194 pneumocystosis 10.0
195 pulmonary edema 10.0
196 cryptococcosis 10.0
197 cellulitis 10.0
198 systemic mastocytosis 10.0
199 mastocytosis 10.0
200 ileus 10.0
201 influenza 10.0
202 herpes zoster 10.0
203 bacterial pneumonia 10.0
204 pulmonary embolism 10.0
205 acute non lymphoblastic leukemia 10.0
206 myelodysplastic syndrome with excess blasts 10.0
207 paraneoplastic syndromes 10.0
208 acute liver failure 10.0
209 invasive aspergillosis 10.0
210 diffuse large b-cell lymphoma 10.0
211 neutropenia 10.0
212 hematopoietic stem cell transplantation 10.0
213 langerhans cell histiocytosis 10.0
214 splenic marginal zone lymphoma 10.0
215 endocarditis 10.0
216 viral pneumonia 10.0
217 strongyloidiasis 10.0
218 tetanus 10.0
219 iron deficiency anemia 10.0
220 nephrotic syndrome 10.0
221 allergic hypersensitivity disease 10.0
222 pulmonary alveolar proteinosis 10.0
223 leukostasis 10.0
224 capillary leak syndrome 10.0
225 cholecystitis 10.0
226 hepatitis 10.0
227 iron metabolism disease 10.0
228 dermatitis 10.0
229 idiopathic interstitial pneumonia 10.0
230 bronchiolitis obliterans 10.0
231 hemoglobinopathy 10.0
232 bronchiolitis 10.0
233 liver disease 10.0
234 acquired immunodeficiency syndrome 10.0
235 cataract 10.0
236 appendicitis 10.0
237 lupus erythematosus 10.0
238 candida glabrata 10.0
239 systemic capillary leak syndrome 10.0
240 paraneoplastic pemphigus 10.0
241 diffuse alveolar hemorrhage 10.0
242 mucositis 10.0
243 beta-thalassemia 9.9
244 ovarian cancer 9.9
245 rheumatoid arthritis 9.9
246 anemia, autoimmune hemolytic 9.9
247 lung cancer 9.9
248 ocular motor apraxia 9.9
249 osteogenic sarcoma 9.9
250 scott syndrome 9.9
251 hypophosphatemia 9.9
252 hyperphosphatemia 9.9
253 paroxysmal nocturnal hemoglobinuria 9.9
254 bone resorption disease 9.9
255 adult respiratory distress syndrome 9.9
256 hemopericardium 9.9
257 pericardial effusion 9.9
258 esophagitis 9.9
259 respiratory syncytial virus infectious disease 9.9
260 acute cystitis 9.9
261 cholestasis 9.9
262 oral candidiasis 9.9
263 squamous cell carcinoma 9.9
264 viral hepatitis 9.9
265 opportunistic mycosis 9.9
266 sensory peripheral neuropathy 9.9
267 cryoglobulinemia 9.9
268 lipid metabolism disorder 9.9
269 purpura 9.9
270 skin disease 9.9
271 lynch syndrome 9.9
272 spindle cell sarcoma 9.9
273 hepatitis e 9.9
274 infertility 9.9
275 hemoglobinuria 9.9
276 progressive multifocal leukoencephalopathy 9.9
277 end stage renal failure 9.9
278 crohn's disease 9.9
279 hypoglycemia 9.9
280 hemophilia 9.9
281 acute myeloblastic leukemia without maturation 9.9
282 dendritic cell tumor 9.9
283 glioma 9.9
284 primary central nervous system lymphoma 9.9
285 t-cell prolymphocytic leukemia 9.9
286 t-cell non-hodgkin lymphoma 9.9
287 glial tumor 9.9
288 secondary pulmonary alveolar proteinosis 9.9
289 pik3ca-related overgrowth syndrome 9.9
290 graft-versus-host disease 9.9
291 follicular lymphoma 9.9
292 thrombocytopenia 9.9
293 severe combined immunodeficiency 9.9
294 acute graft versus host disease 9.9
295 hemoglobin c disease 9.9
296 atrial standstill 1 9.8
297 cardiac arrhythmia 9.8
298 erythroleukemia, familial 9.8
299 factor viii deficiency 9.8
300 hypercalcemia, infantile, 1 9.8
301 mastocytosis, cutaneous 9.8
302 muir-torre syndrome 9.8
303 myositis 9.8
304 neurofibromatosis, type i 9.8
305 noonan syndrome 1 9.8
306 thrombocytopenic purpura, autoimmune 9.8
307 thrombophilia due to activated protein c resistance 9.8
308 wilms tumor 1 9.8
309 hemochromatosis, type 1 9.8
310 proteasome-associated autoinflammatory syndrome 1 9.8
311 rhabdomyosarcoma 2 9.8
312 hemophilia a 9.8
313 ataxia and polyneuropathy, adult-onset 9.8
314 mycobacterium tuberculosis 1 9.8
315 kala-azar 1 9.8
316 human immunodeficiency virus type 1 9.8
317 diabetes mellitus, ketosis-prone 9.8
318 lung cancer susceptibility 3 9.8
319 bacteremia 2 9.8
320 bacterial sepsis 9.8
321 cryptogenic organizing pneumonia 9.8
322 small cell carcinoma 9.8
323 t-cell large granular lymphocyte leukemia 9.8
324 sexual disorder 9.8
325 crohn's colitis 9.8
326 bone disease 9.8
327 angioimmunoblastic t-cell lymphoma 9.8
328 multicentric castleman disease 9.8
329 portal hypertension 9.8
330 lipoid nephrosis 9.8
331 von willebrand's disease 9.8
332 hemolytic-uremic syndrome 9.8
333 coccidioidomycosis 9.8
334 eclampsia 9.8
335 beriberi 9.8
336 lymphadenitis 9.8
337 cryptosporidiosis 9.8
338 leiomyosarcoma 9.8
339 gastroenteritis 9.8
340 thrombophilia 9.8
341 splenic infarction 9.8
342 geotrichosis 9.8
343 glucosephosphate dehydrogenase deficiency 9.8
344 central nervous system disease 9.8
345 liposarcoma 9.8
346 pulmonary fibrosis 9.8
347 granuloma annulare 9.8
348 pleural empyema 9.8
349 arthropathy 9.8
350 gastritis 9.8
351 pyoderma 9.8
352 adult acute lymphocytic leukemia 9.8
353 bronchitis 9.8
354 hypersplenism 9.8
355 chronic kidney disease 9.8
356 peritonitis 9.8
357 paralytic ileus 9.8
358 pyoderma gangrenosum 9.8
359 ulcerative colitis 9.8
360 chronic monocytic leukemia 9.8
361 nervous system disease 9.8
362 hodgkin's lymphoma, mixed cellularity 9.8
363 pyomyositis 9.8
364 rubella 9.8
365 hodgkin's lymphoma, nodular sclerosis 9.8
366 leishmaniasis 9.8
367 bronchiectasis 9.8
368 encephalitis 9.8
369 fasciitis 9.8
370 necrotizing fasciitis 9.8
371 hemorrhoid 9.8
372 sickle cell disease 9.8
373 acquired hemophilia 9.8
374 fournier gangrene 9.8
375 haemophilus influenzae 9.8
376 limbic encephalitis 9.8
377 marek disease 9.8
378 plasma cell leukemia 9.8
379 pseudo-turner syndrome 9.8
380 tetraploidy 9.8
381 headache 9.8
382 rapidly involuting congenital hemangioma 9.8
383 inflammatory myopathy with abundant macrophages 9.8
384 trisomy 1q 9.8
385 exanthem 9.8
386 mantle cell lymphoma 9.8
387 basal cell carcinoma 9.8
388 hairy cell leukemia 9.8
389 chromosomal triplication 9.8
390 thyroid carcinoma 9.8
391 sclerosing liposarcoma 9.8
392 pfeiffer syndrome 9.7
393 meningioma, radiation-induced 9.7
394 meningioma, familial 9.7
395 neutrophilic dermatosis, acute febrile 9.7
396 spinal meningioma 9.7
397 obstructive jaundice 9.7
398 hemangioma 9.7
399 glomerulonephritis 9.7
400 embryonal carcinoma 9.7
401 cutaneous fibrous histiocytoma 9.7
402 benign meningioma 9.7
403 secretory meningioma 9.7
404 lymphoplasmacyte-rich meningioma 9.7
405 histiocytoid hemangioma 9.7
406 lymphoepithelioma-like carcinoma 9.7
407 epithelioid sarcoma 9.7
408 kimura disease 9.7
409 hydroa vacciniforme 9.7
410 posttransplant acute limbic encephalitis 9.7
411 hydroa vacciniforme-like lymphoma 9.7
412 alk-negative anaplastic large cell lymphoma 9.7
413 rare tumor 9.7
414 esophageal cancer 9.7
415 felty syndrome 9.7
416 familial mediterranean fever 9.7
417 stomatin-like protein-2, hyperphosphorylation of 9.7
418 t-cell lymphoma, subcutaneous panniculitis-like 9.7
419 bladder sarcoma 9.7
420 panniculitis 9.7
421 breast fibroadenoma 9.7
422 syringoma 9.7
423 sm-ahnmd 9.7
424 ring chromosome 9.7
425 alk-positive anaplastic large cell lymphoma 9.7
426 discoid lupus erythematosus 9.7
427 autoinflammatory syndrome 9.7
428 neurofibromatosis, type ii 9.7
429 alcohol dependence 9.7
430 alzheimer disease 9.7
431 spondyloarthropathy 1 9.7
432 leukemia, chronic lymphocytic 2 9.7
433 behcet syndrome 9.7
434 cryoglobulinemia, familial mixed 9.7
435 fibrosis of extraocular muscles, congenital, 1 9.7
436 lymphoma, mucosa-associated lymphoid type 9.7
437 gilbert syndrome 9.7
438 endosteal hyperostosis, autosomal dominant 9.7
439 hypertriglyceridemia, familial 9.7
440 ige responsiveness, atopic 9.7
441 mesothelioma, malignant 9.7
442 motion sickness 9.7
443 ataxia-pancytopenia syndrome 9.7
444 osteoporosis 9.7
445 pemphigus vulgaris, familial 9.7
446 polykaryocytosis inducer 9.7
447 porphyria cutanea tarda, type i 9.7
448 porphyria cutanea tarda 9.7
449 dowling-degos disease 1 9.7
450 schistosoma mansoni infection, susceptibility/ 9.7
451 small cell cancer of the lung 9.7
452 smith-magenis syndrome 9.7
453 thyroid cancer, nonmedullary, 1 9.7
454 tuberous sclerosis 1 9.7
455 ataxia-telangiectasia 9.7
456 bloom syndrome 9.7
457 costello syndrome 9.7
458 cryptorchidism, unilateral or bilateral 9.7
459 nijmegen breakage syndrome 9.7
460 nonarteritic anterior ischemic optic neuropathy 9.7
461 reticulum cell sarcoma 9.7
462 schinzel-giedion midface retraction syndrome 9.7
463 sjogren syndrome 9.7
464 thymoma, familial 9.7
465 xeroderma pigmentosum, variant type 9.7
466 sarcoma, synovial 9.7
467 anemia, nonspherocytic hemolytic, due to g6pd deficiency 9.7
468 premature ovarian failure 1 9.7
469 retinitis pigmentosa 11 9.7
470 budd-chiari syndrome 9.7
471 autoimmune lymphoproliferative syndrome 9.7
472 ventricular fibrillation, paroxysmal familial, 1 9.7
473 cervical cancer 9.7
474 alpha-thalassemia 9.7
475 ascaris lumbricoides infection 9.7
476 rheumatoid arthritis, systemic juvenile 9.7
477 creatinine clearance quantitative trait locus 9.7
478 allergic rhinitis 9.7
479 endometrial cancer 9.7
480 autoimmune disease 3 9.7
481 myocardial infarction 9.7
482 major depressive disorder 9.7
483 colorectal cancer, hereditary nonpolyposis, type 2 9.7
484 syndactyly, mesoaxial synostotic, with phalangeal reduction 9.7
485 legius syndrome 9.7
486 bone mineral density quantitative trait locus 8 9.7
487 ewing sarcoma 9.7
488 microvascular complications of diabetes 5 9.7
489 hypotrichosis and recurrent skin vesicles 9.7
490 fatty liver disease, nonalcoholic 1 9.7
491 bone mineral density quantitative trait locus 15 9.7
492 chromosome 8p11 myeloproliferative syndrome 9.7
493 barrett esophagus 9.7
494 dengue virus 9.7
495 membranous nephropathy 9.7
496 schuurs-hoeijmakers syndrome 9.7
497 alacrima, achalasia, and mental retardation syndrome 9.7
498 immunodeficiency, common variable, 10 9.7
499 tatton-brown-rahman syndrome 9.7
500 glucocorticoid resistance, generalized 9.7
501 b-cell expansion with nfkb and t-cell anergy 9.7
502 cataract 44 9.7
503 au-kline syndrome 9.7
504 hydrops, lactic acidosis, and sideroblastic anemia 9.7
505 mirage syndrome 9.7
506 rahman syndrome 9.7
507 diarrhea 9 9.7
508 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.7
509 peripheral vascular disease 9.7
510 angina pectoris 9.7
511 angiosarcoma 9.7
512 sulfonamide allergy 9.7
513 secretory diarrhea 9.7
514 pulmonary aspergilloma 9.7
515 erythema multiforme 9.7
516 familial adenomatous polyposis 9.7
517 restless legs syndrome 9.7
518 autosomal recessive disease 9.7
519 metabolic acidosis 9.7
520 limb ischemia 9.7
521 inflammatory myofibroblastic tumor 9.7
522 autosomal recessive pyridoxine-refractory sideroblastic anemia 2 9.7
523 colitis 9.7
524 ptosis 9.7
525 beta-lactam allergy 9.7
526 waldenstroem's macroglobulinemia 9.7
527 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 9.7
528 nodal marginal zone lymphoma 9.7
529 endometrial hyperplasia 9.7
530 hypogonadotropic hypogonadism 9.7
531 acquired von willebrand syndrome 9.7
532 asymptomatic neurosyphilis 9.7
533 cysticercosis 9.7
534 xerophthalmia 9.7
535 osteomyelitis 9.7
536 dermatomyositis 9.7
537 ehrlichiosis 9.7
538 gastric lymphoma 9.7
539 pre-eclampsia 9.7
540 thrombotic thrombocytopenic purpura 9.7
541 methemoglobinemia 9.7
542 hemiplegia 9.7
543 brucellosis 9.7
544 hydronephrosis 9.7
545 pertussis 9.7
546 vitamin k deficiency bleeding 9.7
547 microcytic anemia 9.7
548 pyelonephritis 9.7
549 cardiac tamponade 9.7
550 listeriosis 9.7
551 cauda equina syndrome 9.7
552 infant gynecomastia 9.7
553 lyme disease 9.7
554 visual epilepsy 9.7
555 mononeuropathy 9.7
556 inflammatory spondylopathy 9.7
557 primary biliary cirrhosis 9.7
558 testicular lymphoma 9.7
559 retroperitoneal lymphoma 9.7
560 graves' disease 9.7
561 dysentery 9.7
562 hepatitis a 9.7
563 hepatic coma 9.7
564 blastomycosis 9.7
565 gynecomastia 9.7
566 telangiectasis 9.7
567 quadriplegia 9.7
568 keratoconjunctivitis sicca 9.7
569 hereditary spherocytosis 9.7
570 balanoposthitis 9.7
571 relapsing fever 9.7
572 paronychia 9.7
573 focal segmental glomerulosclerosis 9.7
574 fungal esophagitis 9.7
575 gout 9.7
576 brain cancer 9.7
577 pneumatosis cystoides intestinalis 9.7
578 porphyria 9.7
579 klebsiella pneumonia 9.7
580 hepatic encephalopathy 9.7
581 urethritis 9.7
582 tuberous sclerosis 9.7
583 amenorrhea 9.7
584 schistosomiasis 9.7
585 poems syndrome 9.7
586 gonadal dysgenesis 9.7
587 pleural disease 9.7
588 urticaria 9.7
589 thrombocytopenia due to platelet alloimmunization 9.7
590 mental depression 9.7
591 histoplasmosis 9.7
592 vascular disease 9.7
593 thyroid gland cancer 9.7
594 neuroendocrine carcinoma 9.7
595 optic nerve disease 9.7
596 hypogonadism 9.7
597 giant cell tumor 9.7
598 pharyngitis 9.7
599 hidradenitis suppurativa 9.7
600 hidradenitis 9.7
601 keratopathy 9.7
602 colon adenocarcinoma 9.7
603 polyclonal hypergammaglobulinemia 9.7
604 macrocytic anemia 9.7
605 motor peripheral neuropathy 9.7
606 relapsing polychondritis 9.7
607 transitional cell carcinoma 9.7
608 acalculous cholecystitis 9.7
609 acquired polycythemia 9.7
610 endometrial adenocarcinoma 9.7
611 newcastle disease 9.7
612 severe acute respiratory syndrome 9.7
613 pulmonary tuberculosis 9.7
614 adenocarcinoma 9.7
615 germ cell cancer 9.7
616 glioblastoma multiforme 9.7
617 interstitial lung disease 9.7
618 ascaridiasis 9.7
619 skin squamous cell carcinoma 9.7
620 lipomatosis 9.7
621 neurilemmoma 9.7
622 chronic granulomatous disease 9.7
623 thymoma 9.7
624 vaccinia 9.7
625 teratocarcinoma 9.7
626 teratoma 9.7
627 mesenchymal cell neoplasm 9.7
628 fibrosarcoma 9.7
629 chondroblastic osteosarcoma 9.7
630 cerebritis 9.7
631 skin carcinoma 9.7
632 turner syndrome 9.7
633 signet ring cell adenocarcinoma 9.7
634 cavernous sinus thrombosis 9.7
635 aortic aneurysm 9.7
636 gastric adenocarcinoma 9.7
637 extramedullary plasmacytoma 9.7
638 cervical squamous cell carcinoma 9.7
639 colonic pseudo-obstruction 9.7
640 adrenal carcinoma 9.7
641 merkel cell carcinoma 9.7
642 thyroid gland papillary carcinoma 9.7
643 spindle cell carcinoma 9.7
644 pancreatic adenocarcinoma 9.7
645 granulomatous dermatitis 9.7
646 extracutaneous mastocytoma 9.7
647 endophthalmitis 9.7
648 embryoma 9.7
649 sebaceous adenocarcinoma 9.7
650 poliomyelitis 9.7
651 myelodysplastic/myeloproliferative neoplasm 9.7
652 thyroid gland disease 9.7
653 liver cirrhosis 9.7
654 ovarian cyst 9.7
655 urinary tract obstruction 9.7
656 gingival hypertrophy 9.7
657 hemoglobin d disease 9.7
658 mature teratoma 9.7
659 aortic valve insufficiency 9.7
660 pediatric lymphoma 9.7
661 paraplegia 9.7
662 conjunctivitis 9.7
663 combined t cell and b cell immunodeficiency 9.7
664 overnutrition 9.7
665 spondylitis 9.7
666 juvenile rheumatoid arthritis 9.7
667 lung lymphoma 9.7
668 mediastinal malignant lymphoma 9.7
669 mature b-cell neoplasm 9.7
670 precursor b lymphoblastic lymphoma/leukemia 9.7
671 thyroiditis 9.7
672 hypogonadotropism 9.7
673 gastrointestinal system disease 9.7
674 hyperthyroidism 9.7
675 myocarditis 9.7
676 periodontitis 9.7
677 arthritis 9.7
678 bullous pemphigoid 9.7
679 reticulosarcoma 9.7
680 perinatal necrotizing enterocolitis 9.7
681 intermediate coronary syndrome 9.7
682 chorioretinitis 9.7
683 skin melanoma 9.7
684 gas gangrene 9.7
685 mast-cell leukemia 9.7
686 priapism 9.7
687 viral infectious disease 9.7
688 acute myocardial infarction 9.7
689 intracranial hypertension 9.7
690 meningitis 9.7
691 pathologic nystagmus 9.7
692 miliary tuberculosis 9.7
693 follicular mucinosis 9.7
694 ltbp4-related cutis laxa 9.7
695 primary familial brain calcification 9.7
696 1q duplications 9.7
697 47, xxy 9.7
698 acquired hemophilia a 9.7
699 acute erythroid leukemia 9.7
700 anca-associated vasculitis 9.7
701 antisynthetase syndrome 9.7
702 b cell prolymphocytic leukemia 9.7
703 blastic plasmacytoid dendritic cell 9.7
704 chromosome 9 inversion 9.7
705 clostridium septicum infection 9.7
706 cold agglutinin disease 9.7
707 congenital cytomegalovirus 9.7
708 glioblastoma 9.7
709 growth hormone deficiency 9.7
710 hhv-6 encephalitis 9.7
711 human t-cell leukemia virus type 1 9.7
712 indolent b cell lymphoma 9.7
713 light chain deposition disease 9.7
714 lymphomatoid granulomatosis 9.7
715 mthfr gene variant 9.7
716 neurosyphilis 9.7
717 oral cancer 9.7
718 pacs1-related syndrome 9.7
719 pemphigus foliaceus 9.7
720 plasmablastic lymphoma 9.7
721 polymyositis 9.7
722 primary biliary cholangitis 9.7
723 pure autonomic failure 9.7
724 rosai-dorfman disease 9.7
725 schinzel giedion syndrome 9.7
726 stevens-johnson syndrome/toxic epidermal necrolysis 9.7
727 systemic onset juvenile idiopathic arthritis 9.7
728 triploidy 9.7
729 wells syndrome 9.7
730 dnmt3a overgrowth syndrome 9.7
731 pacs1 syndrome 9.7
732 depression 9.7
733 dysphagia 9.7
734 hypoxia 9.7
735 seizure disorder 9.7
736 tremor 9.7
737 systemic autoimmune disease 9.7
738 secondary hemophagocytic lymphohistiocytosis 9.7
739 partial deletion of chromosome 9 9.7
740 virus-associated trichodysplasia spinulosa 9.7
741 autoimmune hemolytic anemia, cold type 9.7
742 acute sensory ataxic neuropathy 9.7
743 argyria 9.7
744 bullous pyoderma gangrenosum 9.7
745 hepatosplenic t-cell lymphoma 9.7
746 coronary sinus atresia 9.7
747 primary mediastinal large b-cell lymphoma 9.7
748 acute myeloid leukemia with minimal differentiation 9.7
749 intravascular large b-cell lymphoma 9.7
750 pachyonychia congenita 3 9.7
751 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.7
752 female breast cancer 9.7
753 berylliosis 9.7
754 seminoma 9.7
755 peptic ulcer disease 9.7
756 alopecia areata 9.7
757 hypercholesterolemia, familial, 1 9.7
758 li-fraumeni syndrome 9.7
759 medulloblastoma 9.7
760 gaucher disease, type i 9.7
761 pancreatic cancer 9.7
762 pleuropulmonary blastoma 9.7
763 anxiety 9.7
764 li-fraumeni syndrome 2 9.7
765 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
766 human herpesvirus 8 9.7
767 adrenal cortical carcinoma 9.7
768 dengue shock syndrome 9.7
769 anaplastic large cell lymphoma 9.7
770 lymphoplasmacytic lymphoma 9.7
771 paraganglioma 9.7
772 hemorrhagic cystitis 9.7
773 cardiac arrest 9.7
774 thrombosis 9.7
775 osteonecrosis 9.7
776 mumps 9.7
777 chronic leukemia 9.7
778 prolymphocytic leukemia 9.7
779 respiratory failure 9.7
780 disseminated intravascular coagulation 9.7
781 diarrhea 9.7
782 polyneuropathy 9.7
783 generalized anxiety disorder 9.7
784 cystitis 9.7
785 melanoma 9.7
786 gaucher's disease 9.7
787 agammaglobulinemia 9.7
788 kidney cancer 9.7
789 benign mesothelioma 9.7
790 rhabdomyosarcoma 9.7
791 mood disorder 9.7
792 plasmacytoma 9.7
793 pustulosis of palm and sole 9.7
794 adjustment disorder 9.7
795 adenoma 9.7
796 malignant histiocytosis 9.7
797 measles 9.7
798 subacute delirium 9.7
799 vasculitis 9.7
800 in situ carcinoma 9.7
801 psoriasis 9.7
802 macroglobulinemia 9.7
803 dicer1-related disorders 9.7
804 chronic graft versus host disease 9.7
805 dicer1-related pleuropulmonary blastoma cancer predisposition syndrome 9.7
806 homologous wasting disease 9.7
807 lymphosarcoma 9.7
808 post-transplant lymphoproliferative disease 9.7
809 primary effusion lymphoma 9.7
810 multiple endocrine neoplasia 9.7
811 histiocytic sarcoma 9.7
812 thrombotic microangiopathy 9.7
813 overgrowth syndrome 9.7
814 gallbladder disease 1 9.6
815 sickle cell anemia 9.6
816 hemoglobin h disease 9.6
817 pulmonary hypertension 9.6
818 thymus lymphoma 9.6
819 solitary osseous plasmacytoma 9.6
820 cutaneous mastocytoma 9.6
821 plasma cell tumor 9.6
822 yemenite deaf-blind hypopigmentation syndrome 9.6
823 cortical blindness 9.6
824 paresthesia 9.6
825 bladder cancer 9.5
826 colorectal cancer 9.5
827 hepatocellular carcinoma 9.5
828 enterocolitis 9.5
829 body mass index quantitative trait locus 1 9.5
830 granulomatosis with polyangiitis 9.5
831 pollen allergy 9.5
832 childhood acute lymphocytic leukemia 9.5
833 igg4-related disease 9.5
834 bacterial infectious disease 9.5
835 heart disease 9.5
836 sphingolipidosis 9.5
837 hepatitis b 9.5
838 tic disorder 9.5
839 substance abuse 9.5
840 lysosomal storage disease 9.5
841 embryonal rhabdomyosarcoma 9.5
842 histiocytosis 9.5
843 clear cell sarcoma 9.5
844 juvenile xanthogranuloma 9.5
845 congestive heart failure 9.5
846 hard palate cancer 9.5

Graphical network of the top 20 diseases related to Hematologic Cancer:



Diseases related to Hematologic Cancer
Sources

Symptoms & Phenotypes for Hematologic Cancer

About this section

GenomeRNAi Phenotypes related to Hematologic Cancer according to GeneCards Suite gene sharing:

26 (showing 3, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.1 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.1 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.1 ABL1 FLT3 KIT

MGI Mouse Phenotypes related to Hematologic Cancer:

46 (showing 16, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 ABL1 CBL CSF2 ETV6 FLT3 IL2
2 growth/size/body region MP:0005378 10.36 ABL1 CBL CSF2 ETV6 FLT3 IL2
3 hematopoietic system MP:0005397 10.34 ABL1 CBL CSF2 ETV6 FLT3 IL2
4 immune system MP:0005387 10.3 ABL1 CBL CSF2 ETV6 FLT3 IL2
5 homeostasis/metabolism MP:0005376 10.29 ABL1 CBL CSF2 ETV6 FLT3 IL2
6 cardiovascular system MP:0005385 10.26 ABL1 CBL CSF2 ETV6 IL2 KIT
7 endocrine/exocrine gland MP:0005379 10.26 ABL1 CBL CSF2 ETV6 FLT3 IL2
8 embryo MP:0005380 10.24 ABL1 CSF2 ETV6 JAK2 KIT KMT2A
9 mortality/aging MP:0010768 10.21 ABL1 CBL CSF2 ETV6 FLT3 IL2
10 liver/biliary system MP:0005370 10.06 ABL1 CBL IL2 JAK2 KIT KMT2A
11 integument MP:0010771 10.03 CBL CSF2 ETV6 JAK2 KIT KMT2A
12 neoplasm MP:0002006 10.02 CSF2 ETV6 FLT3 IL2 JAK2 KIT
13 no phenotypic analysis MP:0003012 9.8 ETV6 FLT3 IL2 KIT KMT2A RUNX1
14 normal MP:0002873 9.76 ABL1 ETV6 JAK2 KIT KMT2A PTHLH
15 respiratory system MP:0005388 9.56 ABL1 CBL CSF2 IL2 KIT PTHLH
16 skeleton MP:0005390 9.28 ABL1 CBL CSF2 FLT3 JAK2 KIT
Sources

Drugs & Therapeutics for Hematologic Cancer

About this section

Drugs for Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 546, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
2
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 64778 441130
3
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
4
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
5
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
6
Zinc Approved, Investigational Phase 4 7440-66-6 32051
7
Protein C Approved Phase 4
8
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
9
Busulfan Approved, Investigational Phase 4 55-98-1 2478
10
Bortezomib Approved, Investigational Phase 4 179324-69-7 93860 387447
11
Ofloxacin Approved Phase 4 82419-36-1 4583
12
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
13
Liraglutide Approved Phase 4 204656-20-2 44147092
14
Glucagon Approved Phase 4 16941-32-5
15
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
16
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
17
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
18
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
19 Lactams Phase 4
20 penicillins Phase 4
21 beta-Lactams Phase 4
22 Epoetin alfa Phase 4 113427-24-0
23 Drotrecogin alfa activated Phase 4
24 Thymoglobulin Phase 4
25 Antilymphocyte Serum Phase 4
26 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
27 Cyclooxygenase Inhibitors Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Glucagon-Like Peptide 1 Phase 4
30 Incretins Phase 4
31 Hypoglycemic Agents Phase 4
32 Cyclooxygenase 2 Inhibitors Phase 4
33 Antiparasitic Agents Phase 4
34 Antiprotozoal Agents Phase 4
35 Pharmaceutical Solutions Phase 4
36 14-alpha Demethylase Inhibitors Phase 4
37 Cytochrome P-450 CYP3A Inhibitors Phase 4
38 Cytochrome P-450 Enzyme Inhibitors Phase 4
39 Steroid Synthesis Inhibitors Phase 4
40 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
41 Liposomal amphotericin B Phase 4
42
Hydroxyitraconazole Phase 4
43
Imiquimod Approved, Investigational Phase 2, Phase 3 99011-02-6 57469
44
Tazobactam Approved Phase 3 89786-04-9 123630
45
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
46
Piperacillin Approved Phase 3 66258-76-2 43672
47
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
48
Denosumab Approved Phase 3 615258-40-7
49
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
50
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
51
Febuxostat Approved Phase 3 144060-53-7 134018
52
deoxycholic acid Approved Phase 3 83-44-3 222528
53
Vancomycin Approved Phase 3 1404-90-6 441141 14969
54
Micafungin Approved, Investigational Phase 3 235114-32-6 3081921 477468
55
Daunorubicin Approved Phase 3 20830-81-3 30323
56
Tranexamic Acid Approved Phase 3 1197-18-8 5526
57 Vedolizumab Approved Phase 3 943609-66-3
58
Cilastatin Approved, Investigational Phase 2, Phase 3 82009-34-5 5280454 6435415
59
Imipenem Approved Phase 2, Phase 3 74431-23-5, 64221-86-9 104838
60
Fosaprepitant Approved Phase 3 172673-20-0 219090
61
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
62
Aprepitant Approved, Investigational Phase 3 170729-80-3 151165 6918365
63
Nitrous oxide Approved, Vet_approved Phase 2, Phase 3 10024-97-2 948
64
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
65
Idarubicin Approved Phase 3 58957-92-9 42890
66
Voriconazole Approved, Investigational Phase 3 137234-62-9 71616
67
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
68
Lenalidomide Approved Phase 3 191732-72-6 216326
69
Peginterferon alfa-2b Approved Phase 2, Phase 3 99210-65-8, 215647-85-1
70
Sodium citrate Approved, Investigational Phase 3 68-04-2
71
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
72
leucovorin Approved Phase 3 58-05-9 143 6006
73
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
74
tannic acid Approved Phase 3 1401-55-4
75
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
76
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
77 Daratumumab Approved Phase 3 945721-28-8
78
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
79
Fluorouracil Approved Phase 3 51-21-8 3385
80
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
81
Zoledronic Acid Approved Phase 3 118072-93-8 68740
82
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
83
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793